AGM Statement

 

TIDMCUS 
 
RNS Number : 9890G 
CustomVis plc 
11 February 2010 
 

                                                                11 February 2010 
 
                                  CustomVis plc 
                         ("CustomVis" or "the Company") 
 
                                  AGM Statement 
 
At the Annual General Meeting of CustomVis to be held at 10.00 a.m. this 
morning, Simon Carroll, Chairman of the Company, will make the following 
statement: 
 
 "The Group has made a positive start to 2010, with a further contract for a 
laser into South America, which is quickly becoming one of our strongest 
territories. We continue our endeavours in other countries, where advanced 
negotiations are underway with a number of surgeons, some of which we expect to 
conclude in the coming weeks. 
 
We are very pleased to report that our market opportunities have expanded with 
the regulatory approval to perform our PresBvis(TM) treatment for presbyopia, 
the condition that leads to the need for reading glasses.  Indeed, our CEO, Paul 
van Saarloos, has recently become one of the first patients to undergo 
corrective surgery for presbyopia, using our newly pioneered PresBvis(TM) 
technique. We can report that his vision has been fully restored in the treated 
eye and he no longer needs glasses for reading, something he has done for the 
past 3 years. A key benefit from the ability to perform the PresBvis(TM) 
treatment is that surgeons have another reason to acquire the Pulzar Z1 laser as 
it provides them with another substantial market to address. 
 
The directors expect the rest of the year to be an exciting one for the Group as 
we continue to make advances in our laser technology. We are also now seeing our 
first revenues from PresBvis(TM) and later in the calendar year, we expect to 
make the first sales for RetinaVis(TM), our new portable digital ophthalmoscope 
which photographs the retina of the eye. Negotiations with distributors for 
large volumes are currently underway. 
 
Our key sales focus in 2010 will be on the mature European market, following the 
recent appointment of our European sales representative. This market promises to 
deliver higher margins to the Group and, the current series of clinical trials 
which are underway at Moorfields Hospital should hopefully provide the evidence 
we need to set ourselves favourably against the strongest of our competitors. 
The Moorfields trial is aiming to treat more difficult cases of irregular shaped 
eyes that traditionally have very few or no other options for treatment. 
Therefore, it is likely that the trial will take some time to complete and it is 
unlikely the full results will be available until later this calendar year. 
 
CustomVis plans to announce its interim results in late March, when we will 
update shareholders more thoroughly with our various developments." 
 
                                     -ends- 
 
For further information, please contact: 
 
+---------------------------------+---------------------------------+ 
| CustomVis plc                   |                                 | 
+---------------------------------+---------------------------------+ 
| Simon Carroll, Chairman         |                 [phone] | 
| Paul van Saarloos, CEO          |                 [phone] | 
+---------------------------------+---------------------------------+ 
|                                 |                                 | 
+---------------------------------+---------------------------------+ 
| Merchant John East Securities Limited                             | 
+-------------------------------------------------------------------+ 
| David Worlidge / Simon Clements |                   020 7628 2200 | 
+---------------------------------+---------------------------------+ 
|                                 |                                 | 
+---------------------------------+---------------------------------+ 
| Leander PR                      |                                 | 
+---------------------------------+---------------------------------+ 
| Christian Taylor-Wilkinson      |                   07795 168 157 | 
+---------------------------------+---------------------------------+ 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 AGMBCGDDDSBBGGG